11th International Congress on Infectious Diseases

New Concepts in Infectious Diseases• Use of Phage Lytic Enzymes for theTreatment and Control of B. anthracis andOther PathogensVincent A.Fischetti (USA)

• Wolbachia and Filariasis:The Bacteria Behind the WormMark Taylor (United Kingdom)

• Free Amoeba as Trojan Horses forPneumonia PathogensDidier Raoult (France)

• Persistent Bacterial Infection in the Immunocompetent Host: EfficientGeneration of Antigenic Variants ThroughCombinatorial DiversityGuy Palmer (USA)

The Effects of Antiretroviral Therapy on HIVPrevention: Intended and Unintended Consequences• Impact of HAART on Infectiousness

Kenneth Mayer (USA)• Transmission of Resistant Virus

Luis Soto Ramirez (Mexico)• HIV Post-sexual Exposure Prophylaxis

Mauro Schechter (Brazil)• HIV Risk Behaviors in the Era of HAART

Jonathan Elford (United Kingdom)

ISIDNEWSVolume 7, Number 4 • January 2004

ISID Executive Committee2 0 0 2 – 2 0 0 4

J. P. Butzler (Past Pre s i d e n t )B e l g i u m

K.Christiansen ( P re s i d e n t -E l e c t )Australia

A . Geddes (Tre a s u re r )United Kingdom

E .G o t u z z oP e r u

D. Kasper ( P re s i d e n t )USA

C.E.NordSweden

S. Ponce de LeónMexico

A . Ronald (General Secre t a ry )C a n a d a

J. ShimadaJa p a n

R.WenzelUSA

N o rman Stein( E xe c u t ive Director) U S A

T i m o t hy Brewe r( P rogram Director) U S A

A my Galbl u m( P rogram Coordinator) U S A

ISID NEWSEditorial StaffA my Galbl u mJaylyn OlivoNancy Voy n ov

181 Longwood Ave nu eB o s t o n ,MA 02115-5804 USATe l e p h o n e : (617) 277-05511 (800) 779-8998F a x : (617) 731-1541E-mail:[email protected]://www.isid.org

An Official Publication of the International Society for Infectious Diseases

1

Special Pre-Congress Edition

S Y M P O S I A

Cancun Convention Center and Fiesta Americana Grand Coral Beach Hotel

Science Against SARS• Virology and Pathogenesis of CoronavirusesKen McIntosh (USA)

• Characterization of a Novel CoronavirusCausing Severe Acute RespiratorySyndromePaul Rota (USA)

• Diagnostic Tests for SARSJim LeDuc (USA)

• The SARS Genome and Prospects for Vaccine DevelopmentRino Rappuoli (Italy)

Bioterrorism: Infectious Diseases as Weapons• Emerging Techniques for Rapid Diagnosis of Agents of Bioterrorism(speaker to be confirmed)

• Anthrax Vaccines:Where We Stand and Where We Are Going?Arthur M.Friedlander (USA)

• Designing Surveillance for IdentifyingBioterrorism OutbreaksBob Pinner (USA)

• The Potential Use of Poxviruses inBioterrorismGeoffrey Smith (United Kingdom)

11th International Congress on Infectious DiseasesMarch 4 – 7, 2004 • Cancun, Mexico

continued on page 4

2 ISIDNEWS • January 2004

11th International Congress on Infectious Diseases • Satellite SymposiaMarch 4 – 7, 2004 • Cancun, MexicoCancun Convention Center and Fiesta Americana Grand Coral Beach Hotel

S AT E L L I T E

S Y M P O S I A

Latest Evidence in the Management ofModerate to Severe Intra-abdominal Infections

Breakfast Satellite Symposium sponsored by MSD

Friday, March 5,2004 • 07:00 to 08:15hrsCoral Gallery

• Current Challenges in the Treatment ofCommunity-acquired Mixed InfectionsJose Sifuentes (Mexico)

• Evolving Trends in ResistanceYehuda Carmeli (USA)

• Effective Initial Empiric Treatment of IAIManuel Guzman Blanco (Venezuela)

Meningococcal Disease Prevention—Current Options and Future Prospects

Lunch Satellite Symposium sponsored byChiron Vaccines

Friday , March 5,2004 • 13:00 to 15:00hrsGrand Coral Ballroom 1

• Global Epidemiology of Meningo c o c c a lDisease and Vaccine EfficacyAndrew J. Pollard (United Kingdom)

• Meningococcal C Vaccines:The Canadian ExperiencePhilippe De Wals (Canada)

• The Future of Meningococcal VaccinesLisa Danzig (USA)

• The Strategy to Control New Zealand’sEpidemic of Group B MeningococcalDiseaseJane O’Hallahan (New Zealand)

N e wI n s i g h t s in the Tr e a t m e n t of S e v e r e I n f e c t i o n sin the Multiple Drug-resistant SituationLunch Satellite Symposium sponsored byDaiichi Pharmaceutical Co.,Ltd.

Friday, March 5,2004 • 13:00 to 15:00hrsGrand Coral Ballroom 3

• Comparative Antimicrobial Susceptibilityof Respiratory Tract PathogensDavid Felmingham (United Kingdom)

• Experience with Levofloxacin in aCritical Pathway for the Treatment ofCommunity-acquired PneumoniaThomas J. Marrie (Canada)

• Clinical Applications of Lefofloxacin inSevere InfectionsWolfgang Graninger (Austria)

• New Insights in the Treatment withLevofloxacinThomas File (USA)

Invasive Fungal Infections: A Worldwide ProblemDinner Satellite Symposium sponsored by Pfizer, Inc.


• Early Management Options for SeriousFungal InfectionsJohn Wingard (USA)

• Therapy of Invasive Aspergillosis:Timing Is EverythingBen de Pauw (Netherlands)

• The Impact of Endemic FungalPathogens in the AmericasFlavio Q.Telles (Brazil)

• C l i n i c a l S i g n i f i c a n c e of F u n g a l M e l a n i z a t i o nArturo Casadevall (USA)

ISID would like to acknowledge the following

COLLABORATING AND COOPERATING ORGANIZATIONS11th International Congress on Infectious Diseases

European Society of Clinical Microbioloy and Infectious Diseases (ESCMID)International Society for Anaerobic Bacteria and Infections (ISAB)

Joint United Nations Programme on HIV/AIDS (UNAIDS)Mexican Association of Infectious Diseases and Clinical Microbiology

Mexican Association for the Study and Control of Nosocomial InfectionsMexican Institute of Services and Social Security for Governmental Workers

National Academy of Medicine of MexicoPan American Association of Infectious Diseases (API)

Universidad Nacional Autónoma de México, Facultad de Medicina

ISIDNEWS • January 2004 3

11th International Congress on Infectious Diseases • Satellite SymposiaMarch 4 – 7, 2004 • Cancun, MexicoCancun Convention Center and Fiesta Americana Grand Coral Beach Hotel

S AT E L L I T E

S Y M P O S I A

& P L E N A R Y

L E C T U R E S

Strategies for Early and Appropriate Antibiotic UseDinner Satellite Symposium sponsored by Wyeth


Reassessing AECB Therapy—The Impact ofNew Clinical FindingsBreakfast Satellite Symposium sponsored byBayer HealthCare

Saturday, March 6,2004 • 06:45 to 08:15hrsCoral Gallery

• COPD—The Unrecognized BurdenMarc Miravitlles (Spain)

• Preserving the Efficacy of AntimicrobialsCarlos Amabile-Cuevas (Mexico)

• Short- and Long-term Outcomes—The MOSAIC StudyAntonio Anzueto (USA)

Meningococcal Update: Prevalence andPreventionLunch Satellite Symposium sponsored by BaxterBioScience,Vaccines

Saturday, March 6,2004 • 13:00 to 15:00hrsGrand Coral Ballroom 1

• Bacterial Meningitis in Children andYoung Adults in Latin AmericaCalil Farhat (Brazil)

• Group C Meningococcal Polysaccharide-Tetanus Toxoid (GCMP-TT) ConjugateVaccine (NeisVac-C): Clinical UpdateHartmut Ehrlich (Austria)

• I n t ro d u c t i o n of M e n i n go c o c c a l C C o n j u g a t eVaccines:An Australian PerspectivePeter Richmond (Australia)

Optimizing Outcomes in MRSA Infections:Focus on Nosocomial Pneumonia and Soft Tissue Infections (SSTI)

Lunch Satellite Symposium sponsored by Pfizer, Inc.


• Demystifying the Research:What theClinician Needs to Know aboutResistanceDennis Stevens (USA)

• Successful Strategies for ImprovingSurvival in Nosocomial PneumoniaJordi Rello (Spain)

• A Practical Guide to the Management of Complicated Skin and Soft TissueInfections (SSTIs)Samuel E.Wilson (USA)

On the Road towards Universal MassVaccination against Hepatitis A

Dinner Satellite Symposium sponsored byGlaxoSmithKline


• Review of Current Experience withHepatitis A Universal Mass VaccinationFrancis André (Belgium)

• Combined Hepatitis A & B Vaccines:The Tool to Achieve UMV?Louis Salleras (Spain)

• Burden of Hepatitis A in Latin AmericaMargarita Ramonet (Argentina)

• Is Hepatitis A UMV Cost-effective?(speaker to be confirmed)

Plenary I (Edward H. Kass Lecture)Community-based Therapy for AIDSand Drug-resistant Tuberculosis inResource-poor SettingsPaul Farmer (USA)

Plenary Session IIGenetic Susceptibility to InfectiousDiseases: Genomic ApproachesAdrian Hill (United Kingdom)

Plenary Session IIIReverse Vaccinology: UsingGenome Information toDevelop New VaccinesRino Rappuoli (Italy)

Plenary IVCholera in Latin America:The Paradoxical Benefits of the Last PandemicJaime Sepúlveda (Mexico)

Plenary VOf Flies and Men:The Role of Toll-like Receptors in Innate ImmunityShizuo Akira (Japan)

Plenary VIA Hidden Epidemic:The HTLV-I Story in Latin AmericaEduardo Gotuzzo (Peru)


S Y M P O S I Acontinued from page 1

Advances in Malaria• Malaria Vaccines

Adrian Hill (United Kingdom)• The Role of Var Gene Expression inPathogenesis of MalariaGraham V. Brown (Australia)

• Consequences and Challenges ofChloroquine-resistant MalariaThomas E.Wellems (USA)

• Impact of Drug Resistance on MalariaTreatment and ControlJaime Torres (Venezuela)

Anatomy of an Outbreak: The SARS StoryOrganized in collaboration with World Bank Group

• Global Recognition and Response to NovelPublic Health Threats:The SARS Stor yKlaus Stöhr (Switzerland)

• Epidemiology and Control of SARS in aCommunity:The Canadian ExperienceSusan Poutanen (Canada)

• Clinical Characteristics and Management ofPa t i e n t s with S A R S: L e s s o n s f ro m H o n g Ko n gWing-Hong Seto (China)

• Contingency Planning for a GlobalPa n d e m i c :What International OrganizationsS h o u l d Have Learned from SARSMichael Grizzard (USA)

From the Genome to the Bedside• Use of Genomics and Proteomics toDevelop Better Diagnostic Tools forInfectious Diseases(speaker to be confirmed)

• The Bacterial Genome as a Plan for theDevelopment of New AntibioticsStaffan Normark (Sweden)

• Using the Bacterial Genome to StudyPathogenesisRino Rappuoli (Italy)

• Use of Genomic Information to DevelopNovel Ways of Preventing Complications of InfectionDennis Kasper (USA)

Critical Issues for Infection Control: CurrentReflections• Preparing for Bioterrorism:What HaveWe Learnt During the Past Three Years?Alasdair Geddes (United Kingdom)

• The Rise and Stall of a Failed Policy:TheUS Smallpox Vaccination ProgramCarlos del Rio (USA)

• Tuberculosis in the Hospital: Implicationsof OSHA Withdrawing the ControlMeasuresSamuel Ponce de León (Mexico)

• Have We Eliminated the Threat of PrionDiseases?Andreas Widmer (Switzerland)

• Lessons from the SARS EpidemicRichard Wenzel (USA)

Confronting Pediatric HIV/AIDS GloballyOrganized in collaboration with UNAIDS• Consequences of HIV/AIDS on ChildSurvival with Emphasis on Latin AmericaJesus M. Garcia-Calleja (Switzerland)

• M a n a ging Opportunistic Infections and HIVComplications in Low - re s o u rce SettingsMarinella Della Negra (Brazil)

• S t r a t egies for Initial Therapies and Late Modi-fications in Children Infected with HIVPhilippe Lepage (Belgium)

• E n abling AIDS Orphans to A c h i eve HealthyP ro d u c t ive A d u l t h o o d :A f f o rd able Strategi e sthat Wo r kAurorita Mendoza (Switzerland)

Problems Posed by Newly Identified or Introduced Viruses• Hendra Virus

Joe McCormack (Australia)• Nipah Virus: Bats to Pigs to Men

Paul Kaw Bing Chua (Malaysia)• Manifest Destiny? The Epidemiology ofWest Nile Virus in North AmericaLyle Petersen (USA)

• Other Emerging Ve c t o r - b o rne Viral DiseasesJohn Roehrig (USA)

Expected and Unexpected Disease Outbreaks:Implementing Appropriate Vaccination Strategies• I n f l u e n z a.A Pe rs i s t e n t P l a g u e f o r H u m a n k i n d

Kristin Nicols (USA)• Pneumococcal Vaccines:Widely Known,Widely Under-usedFred Ruben (USA)

• Hepatitis A: Outbreaks and Implications forFuture Vaccine StrategiesEduardo Lopez (Argentina)

• Yellow Fever: Lessons Learned in 2003Eduardo Gotuzzo (Peru)

Innovative Research in Disease Prevention: A Vision for the Future Rotavirus, Human Immunodeficiency Virus• Rotavirus: Developing a Rotavirus Vaccine:Important Immunologic AspectsPaul Offit (USA)

• Rotavirus: Strategy for Rotavirus VaccineDevelopment in the Face of SafetyConcerns about IntussusceptionPenny Heaton (USA)

• HIV: Ongoing Development and Evaluationof a Potential HIV-1 Vaccine Using aReplication-defective Adenoviral VectorMike Robertson (USA)

Innovative Research in Disease Prevention:A Vision for the Future Human Papillomavirus, Herpes Zoster• Human Papillomavirus: Rationale for theIntroduction of Human PapillomavirusVaccines in the Prevention of CervicalCancerNubia Munoz (France)

• Human Papillomavirus: InvestigationalProphylactic Human PapillomavirusVaccines as Tools for Cervical CancerControlMauricio Hernandez Avila (Mexico)

• Herpes Zoster: Epidemiology and Burdenof DiseaseRobert Johnson (United Kingdom)

• Herpes Zoster: Progress Toward Developinga Vaccine to Prevent Herpes ZosterMyron Levin (USA)

11th International Congress on Infectious Diseases • Symposia March 4 – 7, 2004 • Cancun, MexicoCancun Convention Center and Fiesta Americana Grand Coral Beach Hotel


Resistance Surveillance: Local Hot Spots, GlobalStrategies• Surveillance Hot Spots: The Highs andLows of Regional Resistance:–Asia and Far EastJae-Hoon Song (Republic of Korea)–Latin AmericaCelia Alpuche (Mexico)– Australia and New Zealand RegionJohn Turnidge (Australia)

• Factors Behind ResistanceJavier Garau (Spain)

• Surveillance for the Future: GlobalStrategies to Control ResistanceKeith Klugman (USA)

Looking to the Future of RTI Treatment• New Treatment Options for AECB

F. Martinez (USA)• Why Aren’t Clinical Failures Following In Vitro Resistance Patterns?William Bishai (USA)

• Improving Treatment for Sinusitis Patients(speaker to be confirmed)

• Can RTIs Be Treated by a Single Dose ofan Antibiotic?Adriano Arguedas (Costa Rica)

Findings of the Global Pertussis Initiative• Building the Rationale for Pertussis ControlWorldwide and Across the Entire LifespanDanuta Skowronski (Canada)

• Universal Pertussis Immunization:Ensuring Lifelong ProtectionNicole Guiso (France)

• Ta r geted Pe rtussis Immu n i z a t i o n : P reve n t i n gInfection in Close Contacts of NewbornsC.H.Wirsing von König (Germany)

• Economic Burden of Pertussis and theImpact of ImmunizationJaime Caro (USA)

• Pertussis in 2004 and Beyond Kevin Forsyth (Australia)

New Developments in Severe Sepsis• Pathogenesis of Sepsis

Steven Opal (USA)• Identifying Patients with Sepsis

Richard Wenzel (USA)• Novel Experimental Therapies for Sepsis

Jon Cohen (United Kingdom)• Current Therapy of Sepsis

Dennis Maki (USA)

Treating Multi-resistant Gram-positive Cocci:Novel Antimicrobials and Existing Agents• Understanding Mechanisms of EvolvingResistance in Gram-positive BacteriaBarbara Murray (USA)

• Combination Therapy for VRSA and VREFrancis Waldvogel (Switzerland)

• New Agents for the Treatment of Multi-resistant Staphylococci and EnterococciEmilio Bouza (Spain)

• Phytotherapeutics:Are They an Alternative?Thomas Riley (Australia)

Peritonitis• Immunologic Events Resulting in theDevelopment of Bacterial PeritonitisNick Topley (United Kingdom)

• Etiology of Major Complications ofBacterial Peritonitis:Abscesses andAdhesionsArthur Tzianabos (USA)

• Current Status of the Diagnosis andTreatment of Bacterial Peritonitis and ItsComplicationsArmando Vegas (Venezuela)

• The Use of New Anti-infectives in theTreatment of PeritonitisAndrew Onderdonk (USA)

Institutions as Amplification Systems for theSpread of Infectious DiseasesOrganized in collaboration with the European Society ofClinical Microbiology and Infectious Diseases (ESCMID)• HCV Transmission in Prisons:How Much, How Do We Stop It?David Goldberg (United Kingdom)

• MRSA: Changing from an InstitutionallyAcquired to a Community AcquiredPathogenKeryn Christiansen (Australia)

• Nosocomially Acquired Tuberculosis:Recognizing and Preventing TransmissionSigfrido Rangel-Fraustro (Mexico)

• The Role of Institutions in HIV Spread inLow-resource CommunitiesShaheen Mehtar (South Africa)

Challenges to Polio Eradication• Global Eradication:What does it Need to Happen?Jon Andrus (USA)

• U n d e rstanding Immu n o l ogical Cove r a ge forPolio Control:The Role of OPV versus IPVEdwin Asturias (USA)

• IPV versus OPV: Results of the CubanClinical TrialJulio Barrios (Cuba)

• Maintaining Control of Polio in LatinAmerica:The Example of MexicoJose Ignacio Santos (Mexico)

• Implementing IPV in Latin AmericanCountriesLuiza-Helena Falleiros (Brazil)

Infectious Diseases Related to Travel• Emerging Versus Traditional Infections andthe TravelerRobert Steffen (Switzerland)

• Prevention and Recognition of STDsAllan Ronald (Canada)

• Meningococcal Disease: Recent Emergenceof W135Ziad Memish (Saudi Arabia)

• Impact of Drug Resistance on MalariaProphylaxisDavid Freedman (USA)

11th International Congress on Infectious Diseases • SymposiaMarch 4 – 7, 2004 • Cancun, MexicoCancun Convention Center and Fiesta Americana Grand Coral Beach Hotel

ISID would like toacknowledge the

following

SPONSORS11th International

Congress on Infectious Diseases

PREMIER SPONSORS

Chiron VaccinesGlaxoSmithKline

Merck Sharp & DohmePfizer Inc.

SPONSORS

AventisAventis Pasteur

Baxter BioScience,Vaccines

Bayer HealthCareBristol-Myers

Squibb CompanyCubist Pharmaceuticals

Daiichi Pharmaceutical Co., Ltd.

Eli Lilly and CompanyOrtho McNeil

Pharmaceutical, Inc.Wyeth

continued on page 6


Questions and Answers in Invasive Fungal Infections• Are Infections with Resistant YeastsAssociated with Higher Mortality?Vladimir Krcméry (Slovakia)

• New Agents and New Strategies for theTreatment of CandidaRoberto Cauda (Italy)

• Treating Invasive Molds:What’s Availableand What’s ComingJohn Graybill (USA)

• The Role of Molecular Assays in theDiagnosis of Systemic Invasive FungalInfectionsKieren Marr (USA)

Understanding Community-acquired BacterialPneumonia in Children• Challenges to Diagnosing Pneumonia in ChildrenShabir Madhi (South Africa)

• What Is the Gold Standard for theEtiological Diagnosis of Pneumonia?Heikki Peltola (Finland)

• The Value of X-ray in Standardization ofthe Diagnosis of PneumoniaThomas Cherian (Switzerland)

• The Use of Vaccines to Determine theEtiology of PneumoniaRon Dagan (Israel)

Challenges to the Global Detection andSurveillance of Infectious Diseases• Running a Global Infectious DiseasesSurveillance Program:Accomplishmentsand Challenges for WHOStefano Lazzari (Switzerland)

• Regional Networks for the Surveillance of Emerging Diseases and Outbreaks:Regional and International ImpactKumnuan Ungchusak (Thailand)

• The Role of Media and Unofficial Groupsin Emerging Disease Surveillance Marjorie Pollack (USA)

• CDC’s Global Infectious Disease Activitiesand ChallengesTanja Popovic (USA)

Understanding Biofilms and their Role inInfectious DiseasesOrganized in collaboration with the Japanese Associationfor Infectious Diseases• Basic Molecular and Cellular Aspects ofQuorum Sensing Involved in BiofilmFormationBarbara Iglewski (USA)

• Antibiotic Tolerance in Biofilms and itsRole in Persistent InfectionsPhil Stewart (USA)

• Clinical Management and Therapy ofAirway Biofilm DiseaseHiroyuki Kobayashi (Japan)

• Role of Biofilm Po l y s a c c h a rides in Infectiona n d P ro s p e c t s f o r I m mu n o t h e r a p e u t i c C o n t ro lGerald Pier (USA)

Controversies and New Developments in theTreatment of CNS Infections• Bacterial Meningitis: New Trends inEpidemiology and TreatmentCarla Odio (Costa Rica)

• Dexamethasone for Paediatric BacterialMeningitis: Is It Beneficial in DeveolpingCountries?Elizabeth Molyneux (Malawi)

• Oral Glycerol Versus IntravenousDexamethasone for Childhood BacterialMeningitis: Preliminary Results of aClinical TrialIrmeli Roine (Chile)

• Developments in the Diagnosis andManagement of Brain AbscessItzhak Brook (USA)

Antimicrobial-resistant Pathogens: Problems and Solutions• Antibiotic Resistance in Yersinia pestis

Patrice Courvalin (France)• Fluoroquinolone Resistance in Streptococcus

pneumoniaeWing-Hong Seto (China)

• S t r a t egies to Limit A n t i m i c robial Resistancein the Community:What WorksJuan J. Calva (Mexico)

• Evidence-based Control of ResistantNosocomial PathogensKeryn Christiansen (Australia)

The Resistant Pneumococcus and Vaccination—Where Are We in 2004?• The Experience in the USA—4 Years AfterIntroduction of Pneumococcal ConjugateVaccineCynthia Whitney (USA)

• Replacement Phenomenon and AntibioticResistanceKeith Klugman (USA)

• Pneumococcal Conjugate Vaccines andAntibiotic Use in Children—Are TheyRelated?Ron Dagan (Israel)

• Expectations from Countries with HighRates of Antibiotic Resistance Beyond theUSAShabir Madhi (South Africa)

Evolving Drug Resistance in Nosocomial Gram-negative Pathogens• The Permeability Barrier in Gram-negativePathogensKeith Poole (Canada)

• Extended-spectrum Betalactamase-medi-ated Resistance in Enterobacteriaceae andin Gram-negative NonfermentersGabriel Gutkind (Argentina)

• Zinc Carbapenemases as EmergingResistance Determinants in Gram-negativePathogensGian Maria Rossolini (Italy)

• Antimicrobial Options for Treatment ofNosocomial Gram-negative InfectionsCaused by Multidrug-resistant StrainsKaren Bush (USA)

ISID AWARDS

Aventis Pasteur Awards• Alexandre ALCAIS

Paris (France)

• Awo OSAFO-ADDOAccra (Ghana)

The Society gratefully acknowledges the support of AVENTIS PASTEUR, whichmade these awards possible.

Chiron Awards forEpidemiology of Infectious Diseases• Roberto DEBBAG

Buenos Aires (Argentina)

• Maria Eugenia JIMENEZCuernavaca (Mexico)

The Society gratefully acknowledges the support of CHIRON, which made these awards possible.

ISID New InvestigatorAward• Sunil LAL

Delhi (India)


S Y M P O S I A


Health Impact of Food-borne Pathogens• WHO Global Program on Food-borneDiseases SurveillancePeter Braam (Switzerland)

• Non-typhoid Salmonella as a Food-bornePathogenAwa Aidara-Kane (Switzerland)

• The Public Health Impact of CampylobacterHeriberto Fernandez (Chile)

• Clinical and Epidemiological Aspects of E.coli O:157:H7 in Latin AmericaAlejandro Cravioto (Mexico)

Prosthetic-device Infections• Prosthetic-device Infections:Trends and ControversiesDaniel Lew (Switzerland)

• Prosthetic-joint Infections in Limited-resource Hospitals:The Latin AmericaExperienceAbel Jasovich (ARGENTINA)

• Therapy of Different Prosthetic-deviceInfections—The USA ExperienceDouglas Osmon (USA)

• An Algorithm for a Systematic Approachto Prosthetic-device InfectionsWerner Zimmerli (Switzerland)

• C o s t - e f f e c t ive n e s s of Different A p p roaches tothe Therapy of Prosthetic-device InfectionsA.W. Karchmer (USA)

Dengue: A Challenge for Science and PublicHealth in the New Millennium• The Global Resurgence of EpidemicDengue/Dengue Hemorrhagic Fever:A Challenge for the 21st CenturyDuane Gubler (USA)

• Double-edged Sword: Dengue Immunologyand the Pathogenesis of DiseaseAlan Rothman (USA)

• Diagnosing Dengue:What Is Available andWhat Is Coming?María G. Guzmán (Cuba)

• Dengue VaccinesWellington Sun (USA)

Current Aspects of Urinary Tract Infection Therapy• Treatment of Acute Pyelonephritis

Thomas Hooton (USA)• Urinary Tract Infection in Diabetes

Lindsay Nicolle (Canada)• Nosocomial UTI—What Can We Improve?

Florian M.E. Wagenlehner (Germany)• Trends in Resistance of Uropathogens:Clinical RelevanceSilvester Krcméry (Slovakia)

Under Development:• Diseases of the Developing World• Infectious Diseases Challenges in LatinAmerica

IJID Offers RapidReview at CancunConferenceIn an effort to ensure that keyre s e a rch news from theCancun conference reaches aworld-wide audience as soonas possible, IJID is makingavailable a rapid-review facil-ity. Bring your manuscript tothe Society booth by15:00hrs on Friday, March5th and we will ensure thatthe paper is reviewed and aninitial editorial decision isgiven to you by the end ofthe confere n c e. P rov i d i n gthat any revisions are dealt with rapidly by the author,accepted papers can bescheduled for publ i c a t i o nwithin 3 months of the finaldate of acceptance. We hopethis will be of interest and we encourage you to takeadvantage of this facility.

If you anticipate submitting apaper to us at the meeting itwould be helpful to havenotice—please email us [email protected] with detailsof your paper.

We look forward to seeingyou in Cancun.

Prof J CohenDean,Brighton & SussexMedical SchoolIJID Editorial OfficeUniversity of SussexBrighton BN1 9PX, UKTel: +44 (0) 1273 877578Fax:+44 (0) 1273 877576E-mail:[email protected]

ProMED-mail Update by Larry Madoff, MD, Editor

Over 32,000 subscribers. Spurred in part by the wide interest generated in emerging diseases by theSARS outbreak, subscriptions to ProMED-mail rose by 20% in the past 12 months.There are nowover 32,000 subscribers in 150 countries.Thousands more access our website or read reports that areforwarded on to them. In addition to SARS, this year was marked by important reports of avianinfluenza (some causing human disease),monkeypox in the US, and an ongoing outbreak of Ebola inthe Republic of the Congo.

Collaborations with regional networks. ProMED-mail has extended its collaboration with theMekong Basin Disease Surveillance Group. Sponsored by a grant from the Rockefeller Foundation,weare developing a network within the Mekong region to improve reporting of infectious diseases in thisregion,which encompasses Myanmar, Lao PDR,Vietnam, Cambodia,Thailand,and Yunnan provinceof China.As part of this project,ProMED-Mail will also develop collaborations with the East AfricanIntegrated Disease Surveillance Network involving Kenya,Uganda,and Tanzania.

Our efforts to expand coverage in the states of the former Soviet Union continue with liaisons form-ing with two Infectious Disease societies in the Kyrgiz Republic and Ukraine.A Russian-language e-mail service and website are planned for the near future.These efforts are supported by grant supportfrom the Nuclear Threat Initiative.

ProMED-mail Editorial Meeting. ProMED-mail functions virtually, with nearly all of our opera-tions linking 20 staff members in 9 countries occurring via the Internet.There is no substitute, how-ever, for face-to-face encounters, and the ProMED staff will have the chance to meet in conjunctionwith the ICID in Cancun.The meeting will give our subject moderators, editors, and technical staffthe chance to discuss our policies and formulate ways we can work together to strengthen ProMED’sreporting and build our programs.

ProMED-mail Internet-a-thon.This year’s ProMED-mail Internet-a-thon has thus far netted over$50,000.Along with contributions from our individual subscribers, we have also benefited from con-tributions from Aventis-Pasteur and Chiron. Also, in appreciation for ProMED’s extensive SARS cov-erage, the Swiss Federal Office of Public Health made a generous contribution.Our sincere thanks toall of our donors for their support of ProMED-mail.

Send your disease reports.ProMED-mail depends on its readers for news of outbreaks.ISID membersare uniquely positioned to provide us with vital, first-hand information regarding new and emergingdiseases.Please drop us an e-mail at [email protected]


L A S T M A I L I N GAll future issues of ISIDNEWS will be available on the ISID web

page http://www.isid.org or will be e-mailed

to those interested. Please send your e-mail

ADDRESS, complete name, city and country

to [email protected] to receive further issues of

the ISIDNEWS or e-mail reminders when

the new issue is available online.

Thank you for your cooperation.

Saturday March 6, 200410:30–12:30Meeting Room 3, Level 3Cancun Convention CenterMexico

Findings of theGlobal PertussisInitiative

Documents

11th International Congress on Infectious Diseases